ClinicalTrials.gov
ClinicalTrials.gov Menu

Ruxolitinib for Chronic Myeloid Leukemia (CML) With Minimal Residual Disease (MRD)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01751425
Recruitment Status : Recruiting
First Posted : December 18, 2012
Last Update Posted : May 10, 2018
Sponsor:
Collaborator:
Incyte Corporation
Information provided by (Responsible Party):
M.D. Anderson Cancer Center

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : July 2020
  Estimated Study Completion Date : July 2021